TWI734879B - 抗ox40抗體及其用途 - Google Patents

抗ox40抗體及其用途 Download PDF

Info

Publication number
TWI734879B
TWI734879B TW106144235A TW106144235A TWI734879B TW I734879 B TWI734879 B TW I734879B TW 106144235 A TW106144235 A TW 106144235A TW 106144235 A TW106144235 A TW 106144235A TW I734879 B TWI734879 B TW I734879B
Authority
TW
Taiwan
Prior art keywords
antibody
human
antibodies
cells
amino acid
Prior art date
Application number
TW106144235A
Other languages
English (en)
Chinese (zh)
Other versions
TW201825520A (zh
Inventor
費歐那 A 哈汀
Original Assignee
美商艾伯維生物醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾伯維生物醫療股份有限公司 filed Critical 美商艾伯維生物醫療股份有限公司
Publication of TW201825520A publication Critical patent/TW201825520A/zh
Application granted granted Critical
Publication of TWI734879B publication Critical patent/TWI734879B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106144235A 2016-12-15 2017-12-15 抗ox40抗體及其用途 TWI734879B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434761P 2016-12-15 2016-12-15
US62/434,761 2016-12-15

Publications (2)

Publication Number Publication Date
TW201825520A TW201825520A (zh) 2018-07-16
TWI734879B true TWI734879B (zh) 2021-08-01

Family

ID=60937946

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106144235A TWI734879B (zh) 2016-12-15 2017-12-15 抗ox40抗體及其用途

Country Status (37)

Country Link
US (7) US10556962B2 (enExample)
EP (2) EP3504242B1 (enExample)
JP (2) JP6772385B2 (enExample)
KR (2) KR20210157471A (enExample)
CN (1) CN110573527A (enExample)
AR (1) AR110526A1 (enExample)
AU (1) AU2017377036B2 (enExample)
BR (2) BR112019012328A2 (enExample)
CA (1) CA3045940A1 (enExample)
CL (1) CL2019001646A1 (enExample)
CO (1) CO2019007288A2 (enExample)
CR (1) CR20190330A (enExample)
CY (1) CY1123274T1 (enExample)
DK (1) DK3504242T3 (enExample)
DO (1) DOP2019000165A (enExample)
EC (1) ECSP19050049A (enExample)
ES (1) ES2813057T3 (enExample)
HR (1) HRP20201259T1 (enExample)
HU (1) HUE050399T2 (enExample)
IL (1) IL267070A (enExample)
LT (1) LT3504242T (enExample)
MA (1) MA53184A (enExample)
MX (1) MX2019007121A (enExample)
MY (1) MY198059A (enExample)
PE (1) PE20191403A1 (enExample)
PH (1) PH12019501357A1 (enExample)
PL (1) PL3504242T3 (enExample)
PT (1) PT3504242T (enExample)
RS (1) RS60664B1 (enExample)
RU (1) RU2753493C2 (enExample)
SG (1) SG10201914126RA (enExample)
SI (1) SI3504242T1 (enExample)
SM (1) SMT202000462T1 (enExample)
TW (1) TWI734879B (enExample)
UA (1) UA125041C2 (enExample)
UY (1) UY37523A (enExample)
WO (1) WO2018112346A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37523A (es) * 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
CA3066007A1 (en) * 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2020132857A1 (zh) * 2018-12-25 2020-07-02 杭州翰思生物医药有限公司 抗ox40的单克隆抗体及其应用
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
PE20221506A1 (es) 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
CN111303285B (zh) * 2019-12-27 2023-06-02 百力司康生物医药(杭州)有限公司 靶向ox40的抗体及其制备方法和应用
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN113429483A (zh) * 2020-03-23 2021-09-24 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
EP4136116A4 (en) * 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN115461371B (zh) * 2020-06-30 2026-02-13 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN111763258B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 抗ox40抗体及其用途
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
AU2022214914A1 (en) * 2021-01-28 2023-08-17 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
CN117015394A (zh) * 2021-03-12 2023-11-07 博际生物医药科技(杭州)有限公司 结合人TGFβ和PD-L1的双功能分子及其应用
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
EP4366774A4 (en) * 2021-07-09 2025-11-19 Dyne Therapeutics Inc MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
CN118121694B (zh) * 2022-12-01 2026-03-27 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体的注射制剂
CN122080196B (zh) * 2026-04-23 2026-07-24 北京溯本源和生物科技有限公司 一种抗禽流感病毒h7亚型血凝素蛋白的单克隆抗体及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027328A2 (en) * 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
JP6038920B2 (ja) * 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
EP3292152A1 (en) * 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
UY37523A (es) * 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027328A2 (en) * 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

Also Published As

Publication number Publication date
IL267070A (en) 2019-08-29
MX2019007121A (es) 2020-02-05
US10040864B2 (en) 2018-08-07
ECSP19050049A (es) 2019-07-31
SG10201914126RA (en) 2020-02-27
AU2017377036A1 (en) 2019-07-11
UY37523A (es) 2018-07-31
MA53184A (fr) 2021-05-26
CO2019007288A2 (es) 2019-08-20
EP3504242A1 (en) 2019-07-03
HUE050399T2 (hu) 2020-12-28
WO2018112346A1 (en) 2018-06-21
PT3504242T (pt) 2020-08-26
KR20190092552A (ko) 2019-08-07
KR102341926B1 (ko) 2021-12-23
US10556962B2 (en) 2020-02-11
BR122020025629B1 (pt) 2022-05-31
CA3045940A1 (en) 2018-06-21
US20200181282A1 (en) 2020-06-11
LT3504242T (lt) 2020-09-10
CR20190330A (es) 2019-12-19
US20180346593A1 (en) 2018-12-06
PE20191403A1 (es) 2019-10-04
JP2020504101A (ja) 2020-02-06
DOP2019000165A (es) 2019-07-15
ES2813057T3 (es) 2021-03-22
SMT202000462T1 (it) 2020-09-10
AU2017377036B2 (en) 2022-06-23
US20220112304A1 (en) 2022-04-14
DK3504242T3 (da) 2020-08-17
PH12019501357A1 (en) 2020-01-20
US20210017289A1 (en) 2021-01-21
JP6772385B2 (ja) 2020-10-21
RU2019121895A3 (enExample) 2021-02-15
RU2019121895A (ru) 2021-01-15
EP3725809A1 (en) 2020-10-21
CY1123274T1 (el) 2021-12-31
RS60664B1 (sr) 2020-09-30
BR112019012328A2 (pt) 2019-11-19
KR20210157471A (ko) 2021-12-28
EP3504242B1 (en) 2020-06-24
PL3504242T3 (pl) 2020-11-16
CN110573527A (zh) 2019-12-13
CL2019001646A1 (es) 2019-08-23
UA125041C2 (uk) 2021-12-29
MY198059A (en) 2023-07-31
RU2753493C2 (ru) 2021-08-17
US20200048363A1 (en) 2020-02-13
SI3504242T1 (sl) 2020-10-30
US20180171023A1 (en) 2018-06-21
US20180194855A1 (en) 2018-07-12
JP2021019603A (ja) 2021-02-18
HRP20201259T1 (hr) 2020-11-13
US10604584B2 (en) 2020-03-31
AR110526A1 (es) 2019-04-10
TW201825520A (zh) 2018-07-16

Similar Documents

Publication Publication Date Title
US10604584B2 (en) Anti-OX40 antibodies and their uses
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
WO2023116925A1 (en) Novel anti-tslp antibodies
JP2019501883A (ja) 抗体およびその使用方法
RS66234B1 (sr) Anti-ccr8 antitela
TW202037613A (zh) 抗trem1抗體及相關方法
AU2024233726A1 (en) Conditionally activated receptor signaling by using scaffold protein
HK40029314A (en) Anti-ox40 antibodies and their uses
HK40003363B (en) Anti-ox40 antibodies and their uses
HK40003363A (en) Anti-ox40 antibodies and their uses
HK40107549A (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees